Neoleukin Therapeutics Competitors

Neoleukin Therapeutics (NASDAQ:NLTX) and Revance Therapeutics (NASDAQ:RVNC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.

Earnings and Valuation

This table compares Neoleukin Therapeutics and Revance Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Neoleukin Therapeutics has higher revenue and earnings than Revance Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Neoleukin Therapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Neoleukin Therapeutics and Revance Therapeutics, as reported by MarketBeat.

Neoleukin Therapeutics currently has a consensus target price of $22.6667, indicating a potential upside of 89.36%. Revance Therapeutics has a consensus target price of $36.40, indicating a potential upside of 29.40%. Given Neoleukin Therapeutics' higher probable upside, equities analysts clearly believe Neoleukin Therapeutics is more favorable than Revance Therapeutics.

Institutional & Insider Ownership

65.7% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are owned by institutional investors. 7.1% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Revance Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Neoleukin Therapeutics and Revance Therapeutics' net margins, return on equity and return on assets.

Summary

Neoleukin Therapeutics beats Revance Therapeutics on 9 of the 13 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Institutional and Insider Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.7% of Neoleukin Therapeutics shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by company insiders. Comparatively, 7.1% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Dicerna Pharmaceuticals and Neoleukin Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Dicerna Pharmaceuticals and Neoleukin Therapeutics' gross revenue, earnings per share and valuation.

Neoleukin Therapeutics has higher revenue and earnings than Dicerna Pharmaceuticals. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Dicerna Pharmaceuticals and Neoleukin Therapeutics, as reported by MarketBeat.com.

Dicerna Pharmaceuticals currently has a consensus target price of $37.8333, indicating a potential upside of 45.01%. Neoleukin Therapeutics has a consensus target price of $22.6667, indicating a potential upside of 89.36%. Given Neoleukin Therapeutics' higher probable upside, analysts plainly believe Neoleukin Therapeutics is more favorable than Dicerna Pharmaceuticals.

Volatility & Risk

Dicerna Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Axsome Therapeutics (NASDAQ:AXSM) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

63.6% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 65.7% of Neoleukin Therapeutics shares are held by institutional investors. 26.0% of Axsome Therapeutics shares are held by company insiders. Comparatively, 7.1% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Axsome Therapeutics and Neoleukin Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Axsome Therapeutics and Neoleukin Therapeutics' gross revenue, earnings per share and valuation.

Axsome Therapeutics has higher earnings, but lower revenue than Neoleukin Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Axsome Therapeutics and Neoleukin Therapeutics, as reported by MarketBeat.

Axsome Therapeutics currently has a consensus target price of $146.90, indicating a potential upside of 177.22%. Neoleukin Therapeutics has a consensus target price of $22.6667, indicating a potential upside of 89.36%. Given Axsome Therapeutics' higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Neoleukin Therapeutics.

Volatility & Risk

Axsome Therapeutics has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Summary

Neoleukin Therapeutics beats Axsome Therapeutics on 7 of the 12 factors compared between the two stocks.

NGM Biopharmaceuticals (NASDAQ:NGM) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Volatility & Risk

NGM Biopharmaceuticals has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Insider & Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are held by institutional investors. Comparatively, 65.7% of Neoleukin Therapeutics shares are held by institutional investors. 50.4% of NGM Biopharmaceuticals shares are held by company insiders. Comparatively, 7.1% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for NGM Biopharmaceuticals and Neoleukin Therapeutics, as reported by MarketBeat.

NGM Biopharmaceuticals currently has a consensus target price of $39.1111, indicating a potential upside of 53.80%. Neoleukin Therapeutics has a consensus target price of $22.6667, indicating a potential upside of 89.36%. Given Neoleukin Therapeutics' higher probable upside, analysts clearly believe Neoleukin Therapeutics is more favorable than NGM Biopharmaceuticals.

Valuation & Earnings

This table compares NGM Biopharmaceuticals and Neoleukin Therapeutics' gross revenue, earnings per share and valuation.

NGM Biopharmaceuticals has higher revenue and earnings than Neoleukin Therapeutics. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NGM Biopharmaceuticals and Neoleukin Therapeutics' net margins, return on equity and return on assets.

Summary

Neoleukin Therapeutics beats NGM Biopharmaceuticals on 9 of the 15 factors compared between the two stocks.

Neoleukin Therapeutics (NASDAQ:NLTX) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Risk & Volatility

Neoleukin Therapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.

Institutional & Insider Ownership

65.7% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 61.5% of Morphic shares are held by institutional investors. 7.1% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 39.5% of Morphic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for Neoleukin Therapeutics and Morphic, as provided by MarketBeat.com.

Neoleukin Therapeutics presently has a consensus price target of $22.6667, indicating a potential upside of 89.36%. Morphic has a consensus price target of $63.3333, indicating a potential upside of 6.71%. Given Neoleukin Therapeutics' higher possible upside, equities research analysts clearly believe Neoleukin Therapeutics is more favorable than Morphic.

Earnings & Valuation

This table compares Neoleukin Therapeutics and Morphic's revenue, earnings per share (EPS) and valuation.

Morphic has lower revenue, but higher earnings than Neoleukin Therapeutics. Morphic is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neoleukin Therapeutics and Morphic's net margins, return on equity and return on assets.

Summary

Neoleukin Therapeutics beats Morphic on 8 of the 12 factors compared between the two stocks.

Neoleukin Therapeutics (NASDAQ:NLTX) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Risk & Volatility

Neoleukin Therapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500.

Institutional & Insider Ownership

65.7% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 94.7% of Kura Oncology shares are held by institutional investors. 7.1% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 11.0% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for Neoleukin Therapeutics and Kura Oncology, as provided by MarketBeat.com.

Neoleukin Therapeutics presently has a consensus price target of $22.6667, indicating a potential upside of 89.36%. Kura Oncology has a consensus price target of $39.5455, indicating a potential upside of 38.42%. Given Neoleukin Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Neoleukin Therapeutics is more favorable than Kura Oncology.

Earnings & Valuation

This table compares Neoleukin Therapeutics and Kura Oncology's revenue, earnings per share (EPS) and valuation.

Kura Oncology has lower revenue, but higher earnings than Neoleukin Therapeutics. Kura Oncology is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neoleukin Therapeutics and Kura Oncology's net margins, return on equity and return on assets.